In July And August Of 2025, Liquidia Analyzed Interim Data From The 52-week, Prospective, Open-label ASCENT Study Which Fully Enrolled 54 Patients With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

Author: Benzinga Newsdesk | August 12, 2025 06:36am

• Safety data and observed exploratory efficacy data was summarized for Week 8 and Week 16 timepoints. 
• The tolerability profile of YUTREPIA in PH-ILD was consistent with initial observations in the first 20 patients at Week 8. Most patients continued on treatment to Week 16 with 10 of 54 (18.5%) discontinuing the study. 
• There were no discontinuations stemming from drug-related adverse events, such as cough or throat irritation. Of those patients who reported a treatment related cough, 24 of 26 patients reported a mild cough and 2 patients reported a moderate cough. 
• The mean daytime simplified cough scores remained essentially unchanged from baseline through Week 16, suggesting the cough tended to be transient nature. Dose titration remains steady, with a median dose of 132.5 mcg QID at Week 8, and 159 mcg QID at Week 16. 
• The highest exposure at Week 16 was 318 mcg QID. The median improvements in six-minute walk distance were 21.5 meters at Week 8 and 31.5 meters at Week 16. 
• Release of detailed clinical data is targeted for medical conferences in September and October of 2025.

Posted In: LQDA